Vaccines Video Recap—January 23, 2026

This biweekly video recap highlights key advancements in vaccine development, including clinical trials, partnerships, and technological innovations. Significant strides are being made in addressing global health challenges and improving treatment accessibility.

🎯 Watch Our Video Summary Capturing Vaccines News from the Last Two Weeks

Dive deeper

🗓️ Explore weekly details and sources

Week 9–15 January 2026
Week 16–22 January 2026

📚 See the full Vaccines archive on our research hub page.

Transcript

Welcome to the latest edition of Vaccines Research Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

PanChol Cholera Vaccine: PanChol, a live-attenuated cholera vaccine, has demonstrated strong immune responses and good safety and tolerance in a Phase 1 trial. Developed by Mass General Brigham, this vaccine may offer a more effective single-dose alternative to current vaccines, particularly in high-risk populations such as children under 5 in endemic regions. If successful, it could greatly enhance global cholera prevention efforts.

Clover Biopharma RSV+hMPV Vaccine: Clover Biopharma has initiated a Phase 2 trial for its RSV and hMPV vaccine candidates, SCB-1022 and SCB-1033, in Australia. The trial, targeting 420 participants aged 60–85, will evaluate the safety and immunogenicity of the combination vaccine, designed to protect against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). This vaccine could be crucial in safeguarding elderly adults from severe respiratory illness.

Aptar Nasal Vaccine Delivery in COVID-19 Trial: Aptar’s nasal vaccine delivery systems are being used in CastleVax’s Phase II trial for the CVAX-01 intranasal COVID-19 vaccine. The trial will assess the safety, tolerability, and immune response of the vaccine in about 200 participants across the U.S. The nasal delivery system could offer an alternative to injectable mRNA vaccines, potentially improving vaccine accessibility and patient compliance.

AIM Rabies Vaccine: AIM Vaccine’s high-efficiency diploid rabies vaccine has shown significantly higher efficacy in Phase III trials compared to existing products. The use of human diploid cells and advanced purification methods enhances safety and effectiveness, marking a major step forward in rabies prevention. This breakthrough could greatly benefit regions with high rabies incidence.

Immunomic Therapeutics Triple-Negative Breast Cancer Vaccine: Immunomic Therapeutics has received FDA clearance for Phase 1 trials of ITI-5000, an RNA-based vaccine targeting triple-negative breast cancer (TNBC). The vaccine utilizes Immunomic’s UNITE platform to stimulate immune responses against TNBC, a challenging cancer subtype. If successful, it could provide a promising new treatment option for TNBC patients.

Pfizer-Novavax Partnership: Pfizer has signed a $530 million deal to use Novavax’s Matrix-M adjuvant technology in two vaccine programs. This partnership aims to enhance immune responses and improve the effectiveness of vaccines, strengthening Pfizer’s vaccine pipeline and potentially leading to more robust vaccines for various diseases.

Invivyd Long COVID Treatment: Invivyd has announced a Phase 2 trial for VYD2311, a monoclonal antibody targeting Long COVID and vaccine injury. The trial will evaluate the safety and efficacy of VYD2311, which has shown antiviral activity against various SARS-CoV-2 variants. This treatment could provide relief to millions suffering from persistent COVID-19 symptoms.

BioVaxys Ovarian Cancer Vaccine: A novel combination vaccine developed by BioVaxys has shown strong clinical activity in recurrent epithelial ovarian cancer patients. The Phase 1b/2 PESCO trial demonstrated a 40% objective response rate in platinum-sensitive patients, with a 90% disease control rate. This combination therapy could offer a new treatment option for ovarian cancer patients with limited choices.

Stay ahead in Vaccines Research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why it matters

Cholera Vaccine Innovation: PanChol’s promising results could lead to a game-changing vaccine for cholera, especially in regions facing frequent outbreaks.
RSV Vaccine Development: Clover Biopharma’s dual-target vaccine may pave the way for better protection against RSV in older adults, a high-risk group.
Intranasal Vaccine Delivery: Aptar’s collaboration could shift the vaccine landscape, making nasal delivery a viable alternative to injections.
Rabies Vaccine Progress: AIM’s high-efficiency rabies vaccine is a significant leap forward in preventing this deadly disease.
Cancer Immunotherapy: Immunomic’s work in breast cancer could offer new hope for treating difficult-to-treat cancers like TNBC.

🗓️ Explore weekly details and sources

Week 9–15 January 2026
Week 16–22 January 2026

📚 See the full Vaccines archive on our research hub page.

FAQ

What is PanChol and why is it important?

PanChol is a new live-attenuated cholera vaccine that could replace current vaccines with a more effective, single-dose solution, especially for children under 5 who are most vulnerable.

What is the focus of the Phase 2 Clover trial?

The Phase 2 trial of Clover’s RSV + hMPV vaccine candidates will evaluate their safety and immunogenicity in elderly adults, an important population vulnerable to severe respiratory infections.

What role does Pfizer’s deal with Novavax play?

Pfizer’s agreement to use Novavax’s Matrix-M adjuvant in future vaccines could boost the effectiveness of vaccines, offering better immune responses against various pathogens.

Where is the Invivyd Phase 2 trial taking place?

The Phase 2 trial for VYD2311, targeting Long COVID and vaccine injuries, is expected to begin by mid-2026, with participants suffering from chronic symptoms of COVID-19.

Entities / Keywords

Cholera vaccine, RSV, hMPV, COVID-19, Rabies, Triple-negative breast cancer, Vaccine adjuvants, Long COVID, Vaccine delivery systems, Ovarian cancer.